Clinical Trials · NCT06881888
Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema
- Phase
- Phase 1
- Recruitment status
- Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Enrollment
- 0
- Start date
- Aug 2026
- Locations
- 1 site, United States
- Primary endpoint
- Change in macular central subfield thickness